Live
- Gold rates in Visakhapatnam today surges, check the rates on 22 November, 2024
- Satya Kumar flays YSRCP govt for ruining new med colleges
- AP High Court to hear RGVs anticipatory bail plea in social media remarks case
- ICC Champions Trophy: PCB appoints Chief Operating Officer; reiterates stand to host Champions Trophy entirely in Pakistan
- Probe initiated after food poisoning incident
- BGT 2024-25: Nitish Kumar Reddy, Harshit Rana make India Test debuts in first Border-Gavaskar Trophy in Perth
- 100 students fall sick after consuming contaminated food
- TCS will commence ops in Visakha in 3 months: Lokesh
- Pawan, 2 other ministers rule out VSP privatisation
- HC Bench In Kurnool: House passes unanimous resolution
India’s IPR stance promotes affordable medicines: GTRI
New Delhi: India’s stand on intellectual property rights (IPRs) and pharma issues in proposed trade agreements balances innovation with public health...
New Delhi: India’s stand on intellectual property rights (IPRs) and pharma issues in proposed trade agreements balances innovation with public health needs, ensures availability of affordable medicines and promotes growth of generic medicine industry, a GTRI report said on Friday.
Think tank Global Trade Research Initiative (GTRI) said that by opposing demands of developed nations on issues like ‘data exclusivity’ and ‘patent linkage’ in free trade agreements (FTAs), India ensures that generic drug manufacturers get greater market access and cost of life-saving medicines gets reduced significantly.
“India’s approach underscores a commitment to balancing innovation with public health needs, adopting a flexible interpretation of TRIPS to align with its developmental goals, and preventing the establishment of unfair monopolies, especially in the pharmaceutical sector,” the GTRI paper said.
